Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mark A. Stang who wrote (10690)	7/7/1998 8:24:00 PM
From: SHUBLU	Respond to of 23519

Mark- Sound advice to always consider taking profits, but there is also the important aspect of momentum that will take a stock to the next level - in VVUS case I would expect to see the 13-15 range touched in the next few days. Good Luck!

To: Mark A. Stang who wrote (10690)	7/7/1998 8:43:00 PM
From: Patherzen	Respond to of 23519

Vivus Soars on Increased Impotence-Drug Prospects Mountain View, California, July 7 (Bloomberg) -- Vivus Inc. surged 45 percent on expectations that the U.S. Food and Drug Administration approval of a new plant in June will help boost sales of Vivus's impotence treatment, Muse. Vivus shares rose 3 1/8 to 10 in trading of 8.26 million, more than four times the three-month daily average. Charles Olsziewski, an analyst with PaineWebber, raised his rating to ''buy'' from ''neutral.'' The anticipation of competition from Pfizer Inc.'s impotence pill Viagra pushed down Vivus's stock 59 percent in the past year. Viagra started sales in April, quickly dominating the market for impotence treatments. The pill is easier to use than Vivus's Muse, which requires insertion of a drug pellet in the urethra. The tremendous market reception for Viagra, Pfizer's oral medication for impotence, and the publicity surrounding its launch have undoubtedly heightened awareness about this condition within the marketplace,'' Olsziewski wrote in an report. He was not immediately available to comment further. In the report, Olsziewski also wrote that Vivus soon may announce some significant cost changes. These changes could be disclosed when Vivus releases its earnings Thursday, he said. Vivus is based in Mountain View, California. Its new plant is in Lakewood, New Jersey, and was approved on June 25, Vivus said. Once the new plant is operating at full capacity, the combined output of this factory and Vivus's existing one will be five times the output of the original factory, said Nina Ferrari, a Vivus spokeswoman.